Lina Terumi Kubota
About Lina Terumi Kubota
Lina Terumi Kubota is a Sr. Regulatory Affairs Analyst at Bristol Myers Squibb with extensive experience in regulatory affairs for small molecules and biological products.
Current Role at Bristol Myers Squibb
Lina Terumi Kubota is currently serving as a Senior Regulatory Affairs Analyst at Bristol Myers Squibb. She commenced this role in October 2020. In her current position, she leverages her extensive experience in regulatory affairs to support the development and approval of both small molecules and biological products.
Previous Experience at Pharmaceutical Companies
Lina Terumi Kubota previously worked as a Regulatory Affairs Analyst at Bristol Myers Squibb from 2018 to 2020. Prior to that, she held a similar position at Boehringer Ingelheim for 9 months in 2017. Lina also served as a Pharmacovigilance Analyst at Roche from 2012 to 2014. Her roles have primarily been based in São Paulo, Brazil, enabling her to gain a diverse range of experiences in the pharmaceutical industry.
Internships and Early Career
Lina started her career as a Research Intern at the Institute of Biomedical Science/University of Sao Paulo, working there for 11 months from 2010 to 2011. She then spent a year at Johnson & Johnson as a Regulatory Affairs Excellence Intern from 2015 to 2016. These early career experiences provided her with a solid foundation in research and regulatory affairs.
Education and Training
Lina Terumi Kubota completed her Bachelor of Pharmacy (B.Pharm.) at Universidade de São Paulo, studying Pharmacist and Biochemistry from 2010 to 2016. She also pursued extended graduation at St. Francis University, where she studied Healthcare Administration/Management and Public Health from 2014 to 2015. Her education has equipped her with a comprehensive understanding of both pharmaceutical sciences and healthcare management.
Expertise in Regulatory Affairs
Lina has extensive experience in regulatory affairs for both small molecules and biological products. She has a solid background in handling Investigational New Drug (IND) applications. Her roles across multiple renowned pharmaceutical companies have equipped her with the skills and knowledge required to navigate complex regulatory environments effectively.